Chapter 2. Antimicrobial Resistance

Human Surveillance

Key Findings

The Provincial Public Health Laboratories forwarded a total of 4,129 Salmonella isolates (171 serovars) to the National Microbiology Laboratory, Public Health Agency of Canada, for phage typing and susceptibility testing.

Susceptibility testing was carried out on 8 serovars: Enteritidis, Heidelberg, Newport, Paratyphi A, Paratyphi B, Typhi, Typhimurium, and 4,[5],12:i:-. All other isolates have been stored for future susceptibility testing. Summary results are only provided for these serotypes based on analysis conducted on 2,565 isolates.

Human patients aged 50-69 years represented the most common age group for which Salmonella isolates were tested (15%, 564/2,565). Ontario was the province for which the largest proportion of isolates was received (41%, 1,547/2,565). Provincial incidence rates for specific Salmonella serovar infections can be found in Figure 2.

Enteritidis (n = 1,179)

Most common phage types (PT) recovered: PT 8 (31%, 367/1,179), PT 13a (15%, 181/1,179) and atypical Footnote 7 (11%, 134/1,179). Three percent of isolates were recovered from blood; significant increases in isolates from urine were observed in 2012 (3%, 40/1,179) compared to 2011 (2%, 18/951).

Significant increase in resistance to ciprofloxacin was observed compared to 2011, when no resistance was observed. Ten isolates had resistance in 2012 (1%, 10/1,179) compared to 1 isolate observed in 2009 (less than 1%, 1/1,092), the only other time when observed. Different PT were involved (22, 34a, 8, and atypical).

Overall a significant reduction in nalidixic acid resistance was observed between 2011 (15%, 146/951) and 2012 (12%, 145/1,179). Significant decrease was seen in Ontario from 21% (50/236) to 14% (53/374). A total of 9 isolates resistant to ciprofloxacin did not exhibit resistance to nalidixic acid. Less than 1% of the Enteritidis isolates (2/1,179) were resistant to both nalidixic acid and ceftriaxone.

The most common resistance pattern was nalidixic acid (11%, 124/1,179) mainly consisting of PT atypical (40%, 50/124) and PT 1 isolates (24%, 30/124). The pattern involving the greatest number of antimicrobials was AMP-AZM-FOX-TIO-CRO-CIP-GEN-KAN-NAL-SSS-TET-SXT (1 PT 8 isolate from Nova Scotia).


Heidelberg (n = 555)

Most common PT recovered included: PT 19 (54%, 298/555), PT 29 (21%, 114/555) and PT 18 (5%, 25/555) (Figure 3). Phage type 19 significantly increased compared to 2011 (45%, 171/377). Five percent (25/555) of isolates were recovered from urine and 10% (55/555) from blood.

Significant changes in resistance to specific antimicrobials and in specific provinces were observed:

Ceftiofur

  • Decrease from 33% (125/377) in 2011 to 27% (150/555) in 2012
  • Increase from 13% (57/430) in 2006 to 27% (150/555) in 2012
  • Decrease from 33% (181/556) in 2004 to 27% (150/555) in 2012
  • Increase in British Columbia from 12% (2/17) in 2011 to 64% (25/39) in 2012
  • Decrease in Ontario from 35%, (49/140) in 2011 to 16% (35/222) in 2012

 

Amoxicillin-clavulanic acid

  • Decrease from 33% (125/377) in 2011 to 25% (141/555) in 2012
  • Increase in British Columbia from 12% (2/17) in 2011 to 49% (19/39) in 2012
  • Decrease in Ontario from 35% (49/140) in 2011 to 16% (35/222) in 2012

 

Ceftriaxone

  • Decrease from 33% (125/377) in 2011 to 26% (151/555) in 2012
  • Increase in British Columbia from 12% (2/17) in 2011 to 67% (26/39) in 2012
  • Decrease in Ontario from 35% (49/140) in 2011 to 16% (35/222) in 2012

 

Ampicillin

  • Decrease from 41% (153/377) in 2011 to 34% (183/555) in 2012
  • Decrease from 39% (168/430) in 2006 to 33% (183/555) in 2012
  • Decrease from 45% (250/556) in 2004 to 33% (183/555) in 2012
  • Increase in British Columbia from 24% (4/17) in 2011 to 74% (29/39) in 2012
  • Decrease in Ontario from 44% (61/140) in 2011 to 22% (49/222) in 2012

 

For all years combined, 81% (813/995) of resistance to ceftiofur is observed among PT 29, PT 41, PT 4, PT 32, and PT 19. Approximately 70% (2,353/3,405) of all ceftiofur-susceptible strains were among PT 19, 26, atypical, 11, and 5. Overall, resistance to ceftiofur was driven by the increases or decreases of PT 29 among Heidelberg isolates (Figure 3).

The most common resistance pattern was A2C-AMP-CRO (24%, 135/555), followed by the AMP pattern (4%, 24/555). The pattern involving the greatest number of antimicrobials was A2C-AMP-CRO-STR-SSS (1 PT 29 isolate from Manitoba).

Significant changes in age have occurred between 2011 and 2012: 18-29 age group has significantly increased from 9% (34/377) to 14% (79/555) of Heidelberg isolates, while those from patients 70 years and older has significantly decreased from 10% (39/377) to 3% (19/555) (Figure 5).

Newport (n = 149)

The most common PT recovered included: PT 9 (17%, 26/149), atypical (15%, 23/149), and PT 2 (15%, 22/149). Three percent (4/149) of isolates were recovered from urine and 2% (3/149) from blood.

In 2011, decreases were observed in resistance to the A2C-AMP-CRO pattern (amoxicillin-clavulanic acid, ceftiofur, ceftriaxone, ampicillin, and cefoxitin) for British Columbia (21%, 3/14) and Alberta (15%, 3/20) when compared to 2012 (5%, 1/19 and 1/20, respectively). In 2012, nalidixic acid resistance was observed this year in 1 isolate each from Alberta, Saskatchewan, and Ontario only.

There was no nalidixic acid resistance observed in 2011 and only in 1 isolate in 2010.

The most common resistance pattern was ACSSuT-A2C-CRO (5%, 8/149), followed by the NAL (1%, 2/149) and the CHL-KAN-STR-SSS-TET-SXT (1%, 2/149) patterns. The pattern involving the greatest number of antimicrobials was ACSSuT-A2C-CRO-SXT (1 PT 17a isolate from Québec).

Changes in patient age have occurred between 2011 and 2012: the proportion of Newport isolates belonging to the 18-29 age group represented 9% (9/149) of all cases, the lowest percentage observed since 2003 (Figure 6). The total number of isolates in the 30-49 and 50-69 age categories increased between 2011 (17%, 33/193; 17%, 32/193 respectively) and 2012 (20%, 29/149; 21%, 31/149 respectively).

Paratyphi A (n = 38) and Paratyphi B (n = 0)

There were no Paratyphi B isolates received by CIPARS for susceptibility testing in 2012. Sixty-three percent of Paratyphi A isolates (24/38) were recovered from blood samples.

Resistance to ciprofloxacin was observed in 1 Paratyphi A isolate from British Columbia (Table 1). This resistance was previously observed in 1 isolate from Nova Scotia in 2010. Resistance to nalidixic acid significantly increased from 42% (5/12) in 2011 to 95% (36/38) in 2012 (Figure 9).

Typhi (n = 144)

The most common phage types recovered were PT UVS (I+IV) (23%, 33/144), PT E1 (21%, 30/144), PT E9 var. (15%, 21/144). Sixty-nine percent (99/144) of isolates were recovered from blood samples and 1% (1/144) from urine.

Overall, there was a significant increase in ciprofloxacin resistance from 3% (5/197) in 2011 to 10%, (14/144) observed in 2012. A significant increase in ciprofloxacin resistance from 4% (4/103) in 2011 to 17% (13/77) was also observed among isolates from Ontario in 2012.

The most common resistance pattern was resistance to the NAL pattern (58%, 83/144), followed by resistance to AMP-CHL-NAL-STR-SSS-SXT (15%, 22/144).

Significant increases in the proportion of Typhi cases between the ages of 5-12 years were observed from 10% (18/179) in 2010 to 19% (28/144) in 2012 (Figure 7). Smaller changes were also observed among the age group of less than 5 years which increased from 2011 (6%, 13/197) to 2012 (10%, 15/144). A slight decrease among the age group of 50-69 years was observed between 2010 (9%, 17/179) and 2012 (5%, 7/144).

Typhimurium (n = 378)

The most common PT recovered was PT 108 (19%, 70/378), followed by atypical (16%, 60/378) and PT 104 (11%, 43/378). Significant decreases have been observed in PT 104 between 2003 (24%, 146/605) and 2012 (11%, 43/378).

Ciprofloxacin resistance was observed in 3 isolates in 2012 (2 from Ontario and 1 from Newfoundland and Labrador). No resistance was observed in 2011.

Azithromycin resistance was observed in 2 isolates from Ontario (PT 120 and atypical). No resistance to azithromycin was observed in 2011, the first year that susceptibility testing was undertaken for this antimicrobial. Azithromycin resistance was observed in the following resistance patterns: AZM-KAN-TET and AZM-CHL-GEN-KAN-STR-SSS-TET-SXT.

The most common resistance pattern was resistance to ACSSuT (14%, 52/378), followed by resistance to ACKSSuT (3%, 11/378). The pattern involving the greatest number of antimicrobials was ACSSuT-A2C-CRO-GEN-SXT (1 PT U310 isolate from Alberta).

4,[5],12:i:- (n = 122)

The most common PTs recovered were PT 193 (24%, 29/122), PT U291 (21%, 26/122) and atypical (17%, 21/122). Two percent (2/122) of isolates were recovered from urine samples and 1% (1/122) from blood.

Overall, significant decreases were observed among the following antimicrobials between 2011 and 2012:

  • Amoxicillin resistance decreased from 12% (12/104) to 3% (3/122) (Figure 9).
  • Ceftiofur resistance decreased from 12%, (12/104) to 2% (2/122). This decrease in Ontario was from 17% (4/23) to 2% (1/55) (Figure 9).
  • Ceftriaxone resistance decreased from 12% (12/104) to 2% (2/122).
  • Cefoxitin resistance decrease from 12% (12/104) to 2% (2/122).

 

Azithromycin resistance was observed in 3 isolates (1 PT 193 and 1 PT 35 from Ontario, and 1 PT 35 from Prince Edward Island). Resistance to azithromycin was observed in the following resistance patterns: AZM-KAN-TET (1 PT 35 from Ontario and 1 PT 35 from Prince Edward Island) and ACKSSuT-AZM-CIP-GEN-NAL-SXT (1 PT 193 isolate from Ontario).

The most common resistance pattern was AMP-STR-SSS-TET (25%, 31/122), followed by resistance to the TET pattern (9%, 11/122). The pattern involving the greatest number of antimicrobials was ACKSSUT-AZM-CIP-GEN-NAL-SXT (1 PT 193 isolate in Ontario).

Significant changes were observed among cases between the ages of 13-17 years which increased from 1% (1/104) in 2011 to 7% (9/122) of 4,[5],12:i:- isolates in 2012 (Figure 8). Smaller changes were also observed among the 50-69 age class which increased from 8%, (8/104) in 2011 to 16% (20/122) in 2012.

Serovar and Phage Type Distribution

Figure 2. Provincial incidence rates for specific Salmonella serovars in 2012

Provincial incidence rates for specific Salmonella serovars in 2012
Text Equivalent - Figure 2
Province Enteritidis Heidelberg Newport Paratyphi A and B Typhi Typhimurium 4,[5],12:i:-
BC 7.7 1.7 0.4 0.5 0.7 1.1 0.1
AB 9.2 1.9 0.5 0.3 0.4 1.3 0.8
SK 6.0 1.5 0.9 0.1 0.5 1.3 0.5
MB 5.0 1.9 0.2 0.0 0.6 1.5 0.6
ON 5.5 3.3 0.5 0.2 0.6 3.0 0.8
QC 3.5 3.2 0.3 < 0.1 0.1 1.8 0.7
NB 8.5 5.0 0.8 0.0 0.1 0.9 0.7
NS 7.5 3.4 0.3 0.0 0.0 0.9 0.1
PEI 9.6 1.4 0.0 0.0 0.0 2.1 0.7
NL 5.6 3.3 0.2 0.0 0.0 0.6 0.4

Provincial abbreviations are defined in the Preamble.
No S. Newport isolates were received from Prince Edward Island.
No S. Typhi isolates were received from Nova Scotia, Prince Edward Island, and Newfoundland and Labrador.
There were no Paratyphi B isolates received by CIPARS for susceptibility testing in 2012.

Figure 3. Temporal variations of the most common Salmonella Heidelberg phage types

Temporal variations of the most common Salmonella Heidelberg phage types
Text Equivalent - Figure 3
Year 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012
Phage type
29 11% 22% 19% 7% 10% 8% 8% 12% 23% 21%
41 5% 5% 6% 3% 3% 4% 4% 3% 5% 2%
4 4% 2% 1% < 1% 0% 0% 1% 1% 1% < 1%
32 6% 6% 4% 5% 2% 2% 2% 2% < 1% 1%
19 35% 34% 36% 37% 35% 54% 46% 43% 45% 54%
26 9% 3% 4% 4% 7% 2% 3% 7% 2% 2%
Atypical 0% 3% 5% 8% 10% 4% 4% 4% 3% 3%
11 7% 4% 1% 3% 2% 6% 1% 0% 1% 0%
5 1% 2% 2% 4% 2% 8% 4% 3% 1% 1%
Ceftiofur resistance 22% 33% 29% 13% 15% 14% 14% 19% 33% 27%

For Salmonella Heidelberg, the majority of phage types were susceptible to ceftiofur, with the exception of PT 29 which contributed primarily to the observed ceftiofur resistance.

Figure 4. Temporal variations of age groups represented within Salmonella Enteritidis isolates

Temporal variations of age groups represented within Salmonella Enteritidis isolates
Text Equivalent - Figure 4
Year 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012
Age class
Less than 5 9% 10% 7% 7% 6% 9% 7% 6% 5% 6%
5 to 12 9% 13% 11% 9% 10% 5% 9% 8% 6% 7%
13 to 17 4% 5% 6% 5% 5% 18% 5% 5% 4% 4%
18 to 29 13% 17% 17% 18% 16% 22% 15% 13% 13% 14%
30 to 49 31% 28% 20% 35% 28% 7% 22% 17% 18% 14%
50 to 69 18% 17% 19% 21% 15% 17% 19% 15% 17% 17%
70 or older 5% 7% 9% 5% 6% 6% 9% 6% 5% 8%

Figure 5. Temporal variations of age groups represented within Salmonella Heidelberg isolates

Temporal variations of age groups represented within Salmonella Heidelberg isolates
Text Equivalent - Figure 5
Year 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012
Age class
Less than 5 17% 17% 16% 10% 7% 8% 12% 12% 13% 11%
5 to 12 18% 14% 17% 10% 8% 11% 10% 7% 7% 8%
13 to 17 6% 6% 6% 6% 5% 4% 6% 3% 6% 3%
18 to 29 13% 17% 17% 16% 15% 21% 14% 14% 9% 14%
30 to 49 17% 20% 16% 35% 32% 19% 14% 12% 12% 12%
50 to 69 12% 13% 11% 14% 11% 10% 13% 11% 15% 14%
70 or older 9% 9% 10% 9% 8% 9% 14% 6% 10% 3%

Figure 6. Temporal variations of age groups represented within Salmonella Newport isolates

Temporal variations of age groups represented within Salmonella Newport isolates
Text Equivalent - Figure 6
Year 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012
Age class
Less than 5 9% 10% 9% 8% 5% 9% 11% 8% 10% 7%
5 to 12 7% 7% 6% 7% 13% 7% 2% 4% 4% 4%
13 to 17 4% 1% 2% 3% 3% 2% 2% 1% 1% 1%
18 to 29 13% 16% 14% 13% 13% 16% 12% 15% 12% 9%
30 to 49 23% 32% 22% 33% 22% 26% 21% 14% 17% 19%
50 to 69 22% 21% 15% 23% 20% 16% 25% 18% 17% 21%
70 or older 9% 7% 19% 14% 12% 9% 7% 6% 8% 8%

Figure 7. Temporal variations of age groups represented within Salmonella Typhi isolates

Temporal variations of age groups represented within Salmonella Typhi isolates
Text Equivalent - Figure 7
Year 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012
Age class
Less than 5 13% 14% 10% 15% 7% 10% 13% 6% 7% 10%
5 to 12 10% 23% 17% 20% 13% 14% 16% 10% 14% 19%
13 to 17 4% 4% 11% 10% 5% 6% 8% 8% 6% 1%
18 to 29 25% 22% 31% 19% 28% 21% 26% 16% 18% 18%
30 to 49 31% 23% 21% 26% 31% 32% 19% 16% 13% 16%
50 to 69 4% 8% 7% 9% 6% 8% 6% 9% 7% 5%
70 or older 3% 5% 3% 2% 2% 2% 4% 1% 2% 1%

Figure 8. Temporal variations of age groups represented within Salmonella 4,[5],12:i:- isolates

Temporal variations of age groups represented within Salmonella 4,[5],12:i:- isolates
Text Equivalent - Figure 8
Year 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012
Age class
Less than 5 21% 17% 11% 7% 13% 10% 9% 11% 19% 15%
5 to 12 29% 11% 13% 23% 13% 15% 9% 10% 10% 10%
13 to 17 2% 9% 2% 7% 2% 5% 5% 4% 1% 7%
18 to 29 17% 15% 22% 5% 12% 14% 15% 12% 11% 10%
30 to 49 14% 20% 27% 33% 19% 19% 13% 16% 19% 13%
50 to 69 5% 13% 10% 18% 14% 11% 14% 11% 8% 16%
70 or older 10% 11% 8% 7% 4% 10% 9% 5% 5% 4%
Table 1. Number of antimicrobial classes in resistance patterns of Salmonella serovars
Province/serovar Numbers (%)
of isolates
Number of isolates by number of antimicrobial classes in the resistance pattern Number of isolates resistant by antimicrobial class and antimicrobial
Aminoglycosides β-lactams Folate pathway inhibitors Macrolides Phenicols Quinolones Tetracyclines
0 1 2-3 4-5 6-7 GEN KAN STR AMP AMC CRO FOX TIO SSS SXT AZM CHL CIP NAL TET

Antimicrobial abbreviations are defined in the Preamble.
Red, blue, and black numbers indicate isolates resistant to antimicrobials in Categories I, II, and III of importance to human medicine, respectively.
There were no Paratyphi B isolates received by CIPARS for susceptibility testing in 2012.

British Columbia                                          
Enteritidis 178 (57.6) 151 22 1 4 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.4 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.4 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.5 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 2 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.2 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.22 6
Heidelberg 39 (12.6) 9 22 8 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.29 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.19 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.26 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.19 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.25 8
Typhi 33 (10.7) 5 27 1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 1 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.28
Typhimurium 25 (8.1) 15 2 1 7 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.7 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.8 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1 8 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 6 9
Newport 19 (6.1) 16 3 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1 3 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2 3 3
Paratyphi A and B 12 (3.9) 12 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.12
4,[5],12:i:- 3 (1) 2 1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 1 1 3
Total 309 (100) 196 87 10 16 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.4 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.16 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.44 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.20 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.28 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.20 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.27 18 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.5 13 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.4 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.62 29
Alberta
Enteritidis 179 (60.3) 156 17 2 4 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.7 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.10 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.2 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.2 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.2 4 2 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.13 3
Heidelberg 37 (12.5) 18 15 4 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.16 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.15 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.15 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.15 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.15 1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 1 3
Typhimurium 25 (8.4) 12 4 9 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.4 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.12 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.10 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.3 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.3 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.3 13 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2 8 10
Newport 20 (6.7) 18 1 1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1 1 1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 1
Typhi 16 (5.4) 2 8 6 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.6 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.6 7 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.6 6 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.13
4,[5],12:i:- 15 (5.1) 5 5 1 4 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.5 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.4 4 10
Paratyphi A and B 5 (1.7) 5 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.5
Total 297 (100) 211 51 11 24 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.5 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.34 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.47 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.21 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.21 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.21 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.21 30 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.9 18 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.32 27
Saskatchewan
Enteritidis 65 (56) 59 6 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.6
Heidelberg 16 (13.8) 7 9 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.9 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.9 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.9 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.9 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.9
Typhimurium 14 (12.1) 8 2 1 3 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1 4 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2 3 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 3
Newport 10 (8.6) 9 1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 1
4,[5],12:i:- 5 (4.3) 1 4 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.4 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.4 4 4
Typhi 5 (4.3) 2 1 2 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2 3 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3 3 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.5
Paratyphi A and B 1 (0.9) 1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1
Total 116 (100) 84 20 2 10 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.9 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.17 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.10 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.10 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.10 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.10 12 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.6 6 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.14 8
Manitoba
Enteritidis 64 (50.8) 53 9 2 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.9 1
Heidelberg 24 (19) 12 10 2 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.12 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.9 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.10 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.9 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.10 1 1
Typhimurium 19 (15.1) 8 2 1 8 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.9 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.10 9 6 8
4,[5],12:i:- 8 (6.3) 5 2 1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 1 3
Typhi 7 (5.6) 7 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.7
Newport 2 (1.6) 2
Paratyphi A and B 2 (1.6) 2 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2
Total 126 (100) 80 32 5 9 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.11 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.24 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.9 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.10 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.9 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.10 12 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 6 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.18 13
Ontario
Enteritidis 374 (37.1) 307 55 10 2 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.11 8 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.9 1 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.5 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.53 8
Heidelberg 222 (22) 163 51 8 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.7 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.49 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.35 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.35 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.35 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.35 8 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.6 5
Typhimurium 202 (20) 149 5 11 36 1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.7 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.10 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.40 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.37 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1 47 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.10 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2 34 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.2 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.4 46
Typhi 77 (7.6) 7 54 2 14 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.15 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.15 16 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.16 15 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.13 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.68
Newport 64 (6.6) 59 1 1 3 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.3 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.3 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.3 4 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 3 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 4
4,[5],12:i:- 55 (5.5) 37 5 2 10 1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.13 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.13 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.2 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1 12 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2 1 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 15
Paratyphi A and B 15 (1.5) 2 13 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.13
Total 1009 (100) 724 184 34 65 2 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.9 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.13 81 128 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.41 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.40 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.40 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.40 95 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.44 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.4 54 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.21 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.140 78
Québec                                          
Enteritidis 141 (35.4) 106 29 4 2   Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.5   Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1   3 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1     Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.30 5
Heidelberg 128 (32.2) 90 35 3     Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1   Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.35 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.31 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.31 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.31 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.31 2 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1       Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1  
Typhimurium 71 (17.8) 39 5 4 22 1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.4 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.24 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.23 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.2 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.3 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.3 27 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.10   20   Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3 28
4,[5],12:i:- 27 (6.8) 11 1 2 13       Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.13 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.16 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1 13 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2   1     14
Newport 24 (6.0) 21     3       Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.3 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.3 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.3 3 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1   3     3
Typhi 5 (1.3) 5                                      
Paratyphi A and B 2 (0.5)   2                                 2  
Total 398 (100) 272 72 13 40 1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.5 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.45 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.82 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.37 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.39 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.38 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.38 48 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.15   24 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.36 50
New Brunswick                                          
Enteritidis 64 (52.9) 53 8   3       Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.5         3         6 3
Heidelberg 38 (31.4) 20 11 7     Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1   Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.17 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.10 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.12 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.10 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.12 3 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.4         2
Typhimurium 7 (5.8) 2   5     Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1   Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.5           5           1
Newport 6 (5.0) 5     1       Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1 1     1     1
4,[5],12:i:- 5 (4.1) 3 1   1       Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1         2 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1         1
Typhi 1 (0.8) 1                                      
Total 121 (100) 84 20 12 5   Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2   Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.13 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.24 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.11 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.13 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.11 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.13 14 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.5   1   Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.6 8
Nova Scotia                                          
Enteritidis 71 (61.2) 65 5     1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1   Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1   Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1 1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1   Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.6 1
Heidelberg 32 (27.6) 24 7 1         Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.8 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.8 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.8 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.8 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.8              
Typhimurium 9 (7.8) 6   1 2   Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1   Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2         3 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1   2     3
Newport 3 (2.6) 3                                      
4,[5],12:i:- 1 (0.9) 1                                      
Total 116 (100) 99 12 2 2 1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.11 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.8 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.9 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.9 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.9 4 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 2 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.6 4
Prince Edward Island                                          
Enteritidis 14 (66.7) 11 2   1       Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3         1           1
Typhimurium 3 (14.3) 2     1       Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1         1     1     1
Heidelberg 2 (9.5) 2                                      
4,[5],12:i:- 1 (4.8)     1       Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1                 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1       1
Paratyphi A and B 1 (4.8)   1                                 1  
Total 21 (100) 15 3 1 2     Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.4         2   1 1   Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 3
Newfoundland and Labrador                                          
Enteritidis 29 (55.8) 27 1   1       Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1         1           1
Heidelberg 17 (32.7) 8 9             Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.8 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.5 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.5 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.4 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.5           Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1  
Typhimurium 3 (5.8) 2       1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1         1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1   1 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 1
4,[5],12:i:- 2 (3.8) 2                                      
Newport 1 (1.9)   1                                   1
Total 52 (100) 39 11   1 1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.10 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.5 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.5 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.4 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.5 2 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1   1 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2 3

Temporal Antimicrobial Resistance Summary

Figure 9. Temporal variations in resistance of Salmonella serovars from humans

Temporal variations in resistance of Salmonella serovars from humans
Figure 9. Temporal variations in resistance of Salmonella serovars from humans
Serovar Enteritidis   Heidelberg   Newport
Year '03 '04 '05 '06 '07 '08 '09 '10 '11 '12 '03 '04 '05 '06 '07 '08 '09 '10 '11 '12 '03 '04 '05 '06 '07 '08 '09 '10 '11 '12
Number of isolates 352 549 612 710 910 1,258 1,092 995 951 1,179 608 556 409 430 318 290 381 476 377 555 175 152 142 146 127 177 136 135 193 149
Antimicrobial

For the temporal analyses, the proportion (%) of isolates resistant to a specific antimicrobial over the current year has been compared to the proportion (%) of isolates resistant to the same antimicrobial during the first and the previous surveillance year (grey areas). The presence of blue areas indicates significant differences (P ≤ 0.05) for a given antimicrobial.
Additional temporal analyses for ampicillin and ceftiofur were conducted for Salmonella Heidelberg. These two antimicrobials and years (2004 and 2006) were selected due to a change in ceftiofur use practices by Québec chicken hatcheries in early 2005 and in 2007 (start and end of the voluntary period of withdrawal). Significant differences (P ≤ 0.05) observed between the current year results and additional reference year results are indicated by underlined numbers.

Ampicillin Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.2% 4% 2% 3% 2% 3% 2% 2% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.4% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.3%   Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.35% Significant differences (P ≤ 0.05) observed between the current year results and additional reference year results.45% 47% Significant differences (P ≤ 0.05) observed between the current year results and additional reference year results.39% 30% 32% 33% 32% Significant differences (P ≤ 0.05) for a given antimicrobial.41% Significant differences (P ≤ 0.05) for a given antimicrobial. Significant differences (P ≤ 0.05) observed between the current year results and additional reference year results.33%   Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.13% 11% 9% 12% 5% 3% 2% 3% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.7% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.6%
Ceftiofur Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.1% 0% 1% 0% 0% 0% 0% 0% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.22% Significant differences (P ≤ 0.05) observed between the current year results and additional reference year results.33% 29% Significant differences (P ≤ 0.05) observed between the current year results and additional reference year results.13% 15% 14% 14% 19% Significant differences (P ≤ 0.05) for a given antimicrobial.33% Significant differences (P ≤ 0.05) for a given antimicrobial. Significant differences (P ≤ 0.05) observed between the current year results and additional reference year results.27% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.10% 9% 8% 8% 3% 2% 1% 3% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.7% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.6%
Gentamicin Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0% 1% 1% 0% 0% 0% 0% 0% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.4% 1% 1% 3% 3% 2% 4% 1% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.1% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.1% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.1% 1% 1% 0% 0% 1% 0% 0% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0%
Nalidixic acid Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.19% 23% 9% 20% 18% 13% 10% 10% Significant differences (P ≤ 0.05) for a given antimicrobial.15% Significant differences (P ≤ 0.05) for a given antimicrobial.12% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.1% 1% 1% 2% 1% 0% 1% 0% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.3% 1% 0% 5% 2% 1% 0% 1% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.2%
Streptomycin Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.1% 4% 2% 1% 1% 1% 2% 1% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.2% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.2% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.12% 8% 8% 13% 10% 7% 7% 6% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.4% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.3% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.10% 12% 10% 13% 5% 2% 3% 4% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.7% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.8%
Tetracycline Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.3% 5% 2% 4% 6% 2% 1% 2% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.4% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.2% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.15% 16% 11% 13% 7% 6% 5% 3% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.2% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.3% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.13% 13% 10% 18% 9% 4% 4% 6% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.9% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.9%
Trimethoprim-sulfamethoxazole Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.1% 1% 0% 1% 1% 0% 0% 1% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.2% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.1% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.1% 1% 3% 2% 1% 1% 1% 0% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.1% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.2% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.1% 1% 1% 2% 2% 1% 1% 0% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.4% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.3%

Figure 9. Temporal variations in resistance of Salmonella serovars from humans (cont'd)

Temporal variations in resistance of Salmonella serovars from humans
Figure 9. Temporal variations in resistance of Salmonella serovars from humans (cont'd)
Serovar Paratyphi A and B   Typhi
Year '03 '04 '05 '06 '07 '08 '09 '10 '11 '12 '03 '04 '05 '06 '07 '08 '09 '10 '11 '12
Number of isolates 27 43 70 66 45 65 54 30 12 38 127 125 121 164 156 186 160 179 197 144
Antimicrobial

For the temporal analyses, the proportion (%) of isolates resistant to a specific antimicrobial over the current year has been compared to the proportion (%) of isolates resistant to the same antimicrobial during the first and the previous surveillance year (grey areas). The presence of blue areas indicates significant differences (P ≤ 0.05) for a given antimicrobial.
There were no Paratyphi B isolates received by CIPARS for susceptibility testing in 2012.

Ampicillin Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.11% 0% 7% 2% 4% 5% 4% 3% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.8% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0%   Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.10% 16% 26% 18% 21% 17% 18% 16% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.26% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.17%
Ceftiofur Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0% 0% 0% 0% 0% 2% 0% 0% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.1% 0% 0% 1% 0% 0% 1% 0% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.1% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0%
Gentamicin Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0% 0% 0% 0% 0% 2% 0% 0% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0% 0% 0% 0% 0% 0% 0% 0% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0%
Nalidixic acid Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.70% 84% 74% 85% 69% 72% 74% 43% Significant differences (P ≤ 0.05) for a given antimicrobial.42% Significant differences (P ≤ 0.05) for a given antimicrobial.95% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.44% 57% 72% 80% 78% 69% 78% 87% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.87% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.84%
Streptomycin Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.11% 0% 9% 0% 4% 5% 2% 3% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.8% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.10% 16% 27% 14% 21% 18% 16% 16% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.25% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.16%
Tetracycline Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.11% 0% 10% 2% 4% 6% 2% 3% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.8% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.9% 15% 24% 10% 13% 6% 6% 3% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.3% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0%
Trimethoprim-sulfamethoxazole Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.11% 0% 3% 0% 2% 2% 0% 0% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.9% 16% 26% 15% 21% 17% 16% 17% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.27% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.18%

Figure 9. Temporal variations in resistance of Salmonella serovars from humans (cont'd)

Temporal variations in resistance of Salmonella serovars from humans
Figure 9. Temporal variations in resistance of Salmonella serovars from humans (cont'd)
Serovar Typhimurium   4,[5],12:i:-
Year '03 '04 '05 '06 '07 '08 '09 '10 '11 '12 '03 '04 '05 '06 '07 '08 '09 '10 '11 '12
Number of isolates 605 597 559 539 658 474 417 452 361 378 42 46 63 57 85 124 186 163 104 122
Antimicrobial

For the temporal analyses, the proportion (%) of isolates resistant to a specific antimicrobial over the current year has been compared to the proportion (%) of isolates resistant to the same antimicrobial during the first and the previous surveillance year (grey areas). The presence of blue areas indicates significant differences (P ≤ 0.05) for a given antimicrobial.

Ampicillin Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.44% 38% 44% 30% 22% 31% 24% 24% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.24% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.25%   Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.10% 15% 29% 26% 16% 16% 22% 35% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.37% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.33%
Ceftiofur Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.2% 2% 4% 1% 1% 2% 2% 1% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.3% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.2% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.5% 0% 10% 14% 6% 8% 10% 9% Significant differences (P ≤ 0.05) for a given antimicrobial.12% Significant differences (P ≤ 0.05) for a given antimicrobial.2%
Gentamicin Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.1% 2% 2% 1% 2% 3% 1% 1% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.2% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.4% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.5% 7% 2% 2% 0% 5% 2% 1% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.1%
Nalidixic acid Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.1% 1% 3% 2% 3% 2% 3% 2% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.4% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.2% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.0% 7% 0% 4% 4% 2% 1% 1% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.1% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.1%
Streptomycin Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.39% 35% 40% 36% 23% 30% 26% 25% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.27% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.28% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.7% 17% 24% 16% 11% 15% 12% 28% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.23% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.31%
Tetracycline Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.47% 41% 48% 38% 27% 32% 28% 25% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.28% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.29% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.5% 22% 27% 25% 19% 30% 33% 40% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.37% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.42%
Trimethoprim-sulfamethoxazole Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.6% 7% 8% 8% 5% 5% 2% 4% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.4% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.7% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.2% 4% 5% 4% 4% 2% 1% 2% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.3% Percentage of isolates resistant to the same antimicrobial during the first and the previous surveillance year.4%

Minimum Inhibitory Concentrations

More details on how to interpret the minimum inhibitory concentrations (MICs) tables are provided in the CIPARS Annual Report 2012 – Chapter 1. Design and Methods.

Table 2. Distribution of minimum inhibitory concentrations among Salmonella Enteritidis
Antimicrobial n Percentiles % R Distribution (%) of MICs (µg/mL)
MIC 50 MIC 90 ≤ 0.015 0.03 0.06 0.12 0.25 0.5 1 2 4 8 16 32 64 128 256 >256
1Antimicrobial susceptibility breakpoints
2Antimicrobial resistance breakpoints
I Amoxicillin-clavulanic acid 1,179 <=1 <=1 0.2  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.91.6 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.4.8 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.2 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3.1 Table 2 - Footnote 1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.2 Table 2 - Footnote 2 0.2Isolates recovered from sampling activities outside the scope of CIPARS routine (or “core”) surveillance in the specified year.  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Ceftiofur 1,179 1 1 0.3  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2.0 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.93.4 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.4.3 Table 2 - Footnote 1 Table 2 - Footnote 2 0.3Isolates recovered from sampling activities outside the scope of CIPARS routine (or “core”) surveillance in the specified year.  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Ceftriaxone 1,179 <=0.25 <=0.25 0.3  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.99.4 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.2 Table 2 - Footnote 1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.1 Table 2 - Footnote 2 Table 2 - Footnote 2 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.0.1 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.0.2 0.1Isolates recovered from sampling activities outside the scope of CIPARS routine (or “core”) surveillance in the specified year.  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Ciprofloxacin 1,179 <=0.015 0.12 0.8 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.51.2 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.34.5 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.9 Table 2 - Footnote 1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.4.2 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.5.6 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2.6 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.0.4 Table 2 - Footnote 2 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.0.3 0.1Isolates recovered from sampling activities outside the scope of CIPARS routine (or “core”) surveillance in the specified year.  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
II Ampicillin 1,179 <=1 2 3.5  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.70.9 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.25.1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.3 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.2 Table 2 - Footnote 1 Table 2 - Footnote 2 3.5Isolates recovered from sampling activities outside the scope of CIPARS routine (or “core”) surveillance in the specified year.  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Azithromycin 1,179 4 4 0.1  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.5.2 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.89.8 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.4.7 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.2 0.1 Table 2 - Footnote 2Isolates recovered from sampling activities outside the scope of CIPARS routine (or “core”) surveillance in the specified year.  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Cefoxitin 1,179 2 4 0.3  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.4.2 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.84.1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.10.6 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.6 Table 2 - Footnote 1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.1 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.0.3 Table 2 - Footnote 2 0.1Isolates recovered from sampling activities outside the scope of CIPARS routine (or “core”) surveillance in the specified year.  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Gentamicin 1,179 0.50 0.50 0.3  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.31.5 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.66.3 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.9 Table 2 - Footnote 1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.1 Table 2 - Footnote 2 0.3Isolates recovered from sampling activities outside the scope of CIPARS routine (or “core”) surveillance in the specified year.  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Kanamycin 1,179 <=8 <=8 0.3  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.99.7 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.1 Table 2 - Footnote 1 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.0.1 Table 2 - Footnote 2 0.2Isolates recovered from sampling activities outside the scope of CIPARS routine (or “core”) surveillance in the specified year.  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Nalidixic acid 1,179 4 >32 12.3  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.7.3 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.74.9 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3.5 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2.0 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.0.6 Table 2 - Footnote 2 11.7Isolates recovered from sampling activities outside the scope of CIPARS routine (or “core”) surveillance in the specified year.  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Streptomycin 1,179 <=32 <=32 1.9  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.98.1 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.0.5 Table 2 - Footnote 2 1.4Isolates recovered from sampling activities outside the scope of CIPARS routine (or “core”) surveillance in the specified year.  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Trimethoprim-sulfamethoxazole 1,179 <=0.12 <=0.12 1.1  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.97.6 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.1 Table 2 - Footnote 2 1.1Isolates recovered from sampling activities outside the scope of CIPARS routine (or “core”) surveillance in the specified year.  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
III Chloramphenicol 1,179 8 8 0.4  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.2 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.37.9 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.61.0 Table 2 - Footnote 1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.5 Table 2 - Footnote 2 0.4Isolates recovered from sampling activities outside the scope of CIPARS routine (or “core”) surveillance in the specified year.  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Sulfisoxazole 1,179 64 128 2.3 Table 2 - Footnote 2  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2.8 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.26.4 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.59.8 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.8.7 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.1 2.3 Table 2 - Footnote 2Isolates recovered from sampling activities outside the scope of CIPARS routine (or “core”) surveillance in the specified year.
Tetracycline 1,179 <=4 <=4 2.5  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.97.5 Table 2 - Footnote 1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.1 Table 2 - Footnote 2 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.0.1 2.4Isolates recovered from sampling activities outside the scope of CIPARS routine (or “core”) surveillance in the specified year.  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
IV  

Table 3. Distribution of minimum inhibitory concentrations among Salmonella Heidelberg
Antimicrobial n Percentiles % R Distribution (%) of MICs (µg/mL)
MIC 50 MIC 90 ≤ 0.015 0.03 0.06 0.12 0.25 0.5 1 2 4 8 16 32 64 128 256 >256
1Antimicrobial susceptibility breakpoints
2Antimicrobial resistance breakpoints
I Amoxicillin-clavulanic acid 555 ≤ 1 > 32 25.4  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.66.7 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.4 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.7 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.5.0 Table 3 - Footnote 1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.8 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.7.4 Table 3 - Footnote 2 18.0Isolates recovered from sampling activities outside the scope of CIPARS routine (or “core”) surveillance in the specified year.  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Ceftiofur 555 1 > 8 27.0  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.21.8 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.50.3 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.7 Table 3 - Footnote 1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.2 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1.3 Table 3 - Footnote 2 25.8Isolates recovered from sampling activities outside the scope of CIPARS routine (or “core”) surveillance in the specified year.  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Ceftriaxone 555 ≤ 0.25 16 27.2  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.72.8 Table 3 - Footnote 1 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1.3 Table 3 - Footnote 2 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.0.9 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.18.9 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.5.6 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.0.5  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Ciprofloxacin 555 ≤ 0.015 ≤ 0.015 0.0 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.97.8 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.6 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.2 Table 3 - Footnote 1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.2 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.2 Table 3 - Footnote 2  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
II Ampicillin 555 ≤ 1 > 32 33.0  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.65.2 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.6 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.2 Table 3 - Footnote 1 Table 3 - Footnote 2 33.0Isolates recovered from sampling activities outside the scope of CIPARS routine (or “core”) surveillance in the specified year.  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Azithromycin 555 4 4 0.0  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.91.2 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.7.7 Table 3 - Footnote 2
Cefoxitin 555 1 32 25.2  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.53.3 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.18.6 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2.7 Table 3 - Footnote 1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.2 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.19.1 Table 3 - Footnote 2 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.6.1
Gentamicin 555 0.50 1 0.5  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.3 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.76.0 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.21.4 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.5 Table 3 - Footnote 1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.2 Table 3 - Footnote 2 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.0.5
Kanamycin 555 ≤ 8 ≤ 8 0.5  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.99.3 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.2 Table 3 - Footnote 1 Table 3 - Footnote 2 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.0.5
Nalidixic acid 555 4 4 0.4  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.29.7 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.69.2 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.5 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.2 Table 3 - Footnote 2 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.0.4
Streptomycin 555 ≤ 32 ≤ 32 3.2  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.96.8 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1.4 Table 3 - Footnote 2 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1.8
Trimethoprim-sulfamethoxazole 555 ≤ 0.12 ≤ 0.12 2.2  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.97.7 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.2 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.0.2 Table 3 - Footnote 2 2.0Isolates recovered from sampling activities outside the scope of CIPARS routine (or “core”) surveillance in the specified year.  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
III Chloramphenicol 555 8 8 0.2  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.2 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.26.7 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.72.4 Table 3 - Footnote 1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.5 Table 3 - Footnote 2 0.2Isolates recovered from sampling activities outside the scope of CIPARS routine (or “core”) surveillance in the specified year.  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Sulfisoxazole 555 32 64 2.7  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.9.9 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.67.7 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.18.7 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.9 2.7 Table 3 - Footnote 2Isolates recovered from sampling activities outside the scope of CIPARS routine (or “core”) surveillance in the specified year.
Tetracycline 555 ≤ 4 ≤ 4 3.4  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.96.6 Table 3 - Footnote 1 Table 3 - Footnote 2 3.4Isolates recovered from sampling activities outside the scope of CIPARS routine (or “core”) surveillance in the specified year.  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
IV  

Table 4. Distribution of minimum inhibitory concentrations among Salmonella Newport
Antimicrobial n Percentiles % R Distribution (%) of MICs (µg/mL)
MIC 50 MIC 90 ≤ 0.015 0.03 0.06 0.12 0.25 0.5 1 2 4 8 16 32 64 128 256 >256
1Antimicrobial susceptibility breakpoints
2Antimicrobial resistance breakpoints
I Amoxicillin-clavulanic acid 149 <=1 <=1 6.0  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.92.6 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.7 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.7  Table 4 - Footnote 1 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.2.7 Table 4 - Footnote 2 3.4Isolates recovered from sampling activities outside the scope of CIPARS routine (or “core”) surveillance in the specified year.  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Ceftiofur 149 1 1 6.0  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.26.2 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.67.8  Table 4 - Footnote 1 Table 4 - Footnote 2 6.0Isolates recovered from sampling activities outside the scope of CIPARS routine (or “core”) surveillance in the specified year.  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Ceftriaxone 149 <=0.25 <=0.25 6.0 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.93.3 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.7  Table 4 - Footnote 1 Table 4 - Footnote 2 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.4.7 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1.3
Ciprofloxacin 149 <=0.015 <=0.015 0.0 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.93.3 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2.0  Table 4 - Footnote 1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2.7 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.7 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.3 Table 4 - Footnote 2
II Ampicillin 149 <=1 <=1 6.0  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.92.6 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.3  Table 4 - Footnote 1 Table 4 - Footnote 2 6.0Isolates recovered from sampling activities outside the scope of CIPARS routine (or “core”) surveillance in the specified year.  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Azithromycin 149 4 4 0.0  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.13.4 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.83.9 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2.7 Table 4 - Footnote 2Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Cefoxitin 149 2 2 6.0  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.31.5 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.59.1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3.4  Table 4 - Footnote 1 Table 4 - Footnote 2 6.0Isolates recovered from sampling activities outside the scope of CIPARS routine (or “core”) surveillance in the specified year.  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Gentamicin 149 0.50 0.50 0.0  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2.7 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.88.6 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.8.7  Table 4 - Footnote 1 Table 4 - Footnote 2  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Kanamycin 149 <=8 <=8 2.0  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.98.0  Table 4 - Footnote 1 Table 4 - Footnote 2 2.0Isolates recovered from sampling activities outside the scope of CIPARS routine (or “core”) surveillance in the specified year.  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Nalidixic acid 149 4 4 2.0  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.45.0 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.51.0 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.7 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.3 Table 4 - Footnote 2 2.0Isolates recovered from sampling activities outside the scope of CIPARS routine (or “core”) surveillance in the specified year.  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Streptomycin 149 <=32 <=32 8.1  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.91.9 Table 4 - Footnote 2 8.1Isolates recovered from sampling activities outside the scope of CIPARS routine (or “core”) surveillance in the specified year.
Trimethoprim-sulfamethoxazole 149 <=0.12 <=0.12 3.4  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.96.6 Table 4 - Footnote 2 3.4Isolates recovered from sampling activities outside the scope of CIPARS routine (or “core”) surveillance in the specified year.  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
III Chloramphenicol 149 4 8 7.4  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.71.1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.21.5 Table 4 - Footnote 1 Table 4 - Footnote 2 7.4Isolates recovered from sampling activities outside the scope of CIPARS routine (or “core”) surveillance in the specified year.  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Sulfisoxazole 149 64 128 8.7  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3.4 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.27.5 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.54.4 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.5.4 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.7 8.7 Table 4 - Footnote 2Isolates recovered from sampling activities outside the scope of CIPARS routine (or “core”) surveillance in the specified year.
Tetracycline 149 <=4 <=4 9.4  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.90.6 Table 4 - Footnote 1 Table 4 - Footnote 2 9.4Isolates recovered from sampling activities outside the scope of CIPARS routine (or “core”) surveillance in the specified year.  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
IV  

Table 5. Distribution of minimum inhibitory concentrations among Salmonella Paratyphi A
Antimicrobial n Percentiles % R Distribution (%) of MICs (µg/mL)
MIC 50 MIC 90 ≤ 0.015 0.03 0.06 0.12 0.25 0.5 1 2 4 8 16 32 64 128 256 >256
1Antimicrobial susceptibility breakpoints
2Antimicrobial resistance breakpoints
I Amoxicillin-clavulanic acid 38 2 2 0.0  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.31.6 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.68.4  Table 5 - Footnote 1 Table 5 - Footnote 2  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Ceftiofur 38 1 1 0.0  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.100.0  Table 5 - Footnote 1 Table 5- Footnote 2  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Ceftriaxone 38 <=0.25 <=0.25 0.0  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.97.4 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2.6  Table 5 - Footnote 1 Table 5 - Footnote 2  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Ciprofloxacin 38 0.50 0.50 2.6 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2.6 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2.6  Table 5 - Footnote 1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.92.1 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.2.6 Table 5 - Footnote 2  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
II Ampicillin 38 2 2 0.0  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.5.3 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.94.7  Table 5 - Footnote 1  Table 5 - Footnote 2  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Azithromycin 38 4 8 0.0  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.57.9 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.42.1  Table 5 - Footnote 2Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Cefoxitin 38 4 8 0.0  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2.6 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.76.3 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.21.1 Table 5 - Footnote 1 Table 5 - Footnote 2  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Gentamicin 38 <=0.25 <=0.25 0.0  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.97.4 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2.6   Table 5 - Footnote 1 Table 5 - Footnote 2  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Kanamycin 38 <=8 <=8 0.0  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.100.0  Table 5 - Footnote 1   Table 5 - Footnote 2  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Nalidixic acid 38 >32 >32 94.7  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2.6 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2.6 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.10.5 Table 5 - Footnote 2 84.2Isolates recovered from sampling activities outside the scope of CIPARS routine (or “core”) surveillance in the specified year.  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Streptomycin 38 <=32 <=32 0.0  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.100.0  Table 5 - Footnote 2  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Trimethoprim-sulfamethoxazole 38 <=0.12 <=0.12 0.0  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.94.7 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.5.3  Table 5 - Footnote 2  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
III Chloramphenicol 38 8 8 0.0  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.94.7 Table 5 - Footnote 1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.5.3  Table 5 - Footnote 2  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Sulfisoxazole 38 64 64 0.0  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2.6 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.44.7 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.52.6  Table 5 - Footnote 2Discontinuation or no surveillance activity
Tetracycline 38 <=4 <=4 0.0  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.100.0 Table 5 - Footnote 1  Table 5 - Footnote 2  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
IV  

Table 6. Distribution of minimum inhibitory concentrations among Salmonella Typhi
Antimicrobial n Percentiles % R Distribution (%) of MICs (µg/mL)
MIC 50 MIC 90 ≤ 0.015 0.03 0.06 0.12 0.25 0.5 1 2 4 8 16 32 64 128 256 >256
1Antimicrobial susceptibility breakpoints
2Antimicrobial resistance breakpoints
I Amoxicillin-clavulanic acid 144 <=1 8 0.0  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.83.3 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.4 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.15.3 Table 6 - Footnote 1  Table 6 - Footnote 2  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Ceftiofur 144 0.50 1 0.0  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.61.8 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.38.2  Table 6 - Footnote 1  Table 6 - Footnote 2  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Ceftriaxone 144 <=0.25 <=0.25 0.0  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.100.0  Table 6 - Footnote 1  Table 6 - Footnote 2  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Ciprofloxacin 144 0.25 0.50 9.7 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.15.3  Table 6 - Footnote 1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.6.9 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.40.3 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.27.8 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.2.8 Table 6 - Footnote 2 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.0.7 6.3Isolates recovered from sampling activities outside the scope of CIPARS routine (or “core”) surveillance in the specified year.  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
II Ampicillin 144 <=1 >32 16.7  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.83.3  Table 6 - Footnote 1  Table 6 - Footnote 2 16.7Isolates recovered from sampling activities outside the scope of CIPARS routine (or “core”) surveillance in the specified year.  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Azithromycin 144 4 4 0.0  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.7 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.35.4 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.61.8 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2.1  Table 6 - Footnote 2Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Cefoxitin 144 4 8 0.0  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.29.9 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.7.6 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.43.1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.18.8 Table 6 - Footnote 1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.7  Table 6 - Footnote 2  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Gentamicin 144 0.50 0.50 0.0  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.49.3 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.50.7   Table 6 - Footnote 1  Table 6 - Footnote 2  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Kanamycin 144 <=8 <=8 0.0  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.100.0  Table 6 - Footnote 2  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Nalidixic acid 144 >32 >32 84.0  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2.1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.11.8 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.4 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.7 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.0.7 Table 6 - Footnote 2 83.3Isolates recovered from sampling activities outside the scope of CIPARS routine (or “core”) surveillance in the specified year.  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Streptomycin 144 <=32 >64 16.0  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.84.0  Table 6 - Footnote 2 16.0Isolates recovered from sampling activities outside the scope of CIPARS routine (or “core”) surveillance in the specified year.  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Trimethoprim-sulfamethoxazole 144 <=0.12 >4 18.1  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.81.3 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.7  Table 6 - Footnote 2 18.1Isolates recovered from sampling activities outside the scope of CIPARS routine (or “core”) surveillance in the specified year.  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
III Chloramphenicol 144 8 >32 17.4  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.7 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.47.2 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.34.7 Table 6 - Footnote 1  Table 6 - Footnote 2 17.4Isolates recovered from sampling activities outside the scope of CIPARS routine (or “core”) surveillance in the specified year.  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Sulfisoxazole 144 64 >256 18.8  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.8.3 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.37.5 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.31.3 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3.5 0.7 18.8 Table 6 - Footnote 2Isolates recovered from sampling activities outside the scope of CIPARS routine (or “core”) surveillance in the specified year.
Tetracycline 144 <=4 <=4 0.0  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.100.0 Table 6 - Footnote 1  Table 6 - Footnote 2  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
IV  

Table 7. Distribution of minimum inhibitory concentrations among Salmonella Typhimurium
Antimicrobial n Percentiles % R Distribution (%) of MICs (µg/mL)
MIC 50 MIC 90 ≤ 0.015 0.03 0.06 0.12 0.25 0.5 1 2 4 8 16 32 64 128 256 >256
1Antimicrobial susceptibility breakpoints
2Antimicrobial resistance breakpoints
I Amoxicillin-clavulanic acid 378 <=1 16 1.9  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.70.1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.4.5 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.4.8 Table 7 - Footnote 1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.17.7  Table 7 - Footnote 2 1.9Isolates recovered from sampling activities outside the scope of CIPARS routine (or “core”) surveillance in the specified year.  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Ceftiofur 378 1 1 2.4  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.11.6 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.81.7 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.4.2 Table 7 - Footnote 1  Table 7 - Footnote 2 2.4Isolates recovered from sampling activities outside the scope of CIPARS routine (or “core”) surveillance in the specified year.  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Ceftriaxone 378 <=0.25 <=0.25 2.4  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.97.1   Table 7 - Footnote 1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.5  Table 7 - Footnote 2 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1.1 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1.1 0.3Isolates recovered from sampling activities outside the scope of CIPARS routine (or “core”) surveillance in the specified year.  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Ciprofloxacin 378 <=0.015 0.03 0.8 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.87.8 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.7.4 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.8 Table 7 - Footnote 1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.5 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.3 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.3 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.0.8 Table 7 - Footnote 2  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
II Ampicillin 378 <=1 >32 24.9  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.67.5 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.4.5 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2.4   Table 7 - Footnote 1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.8 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.0.3 Table 7 - Footnote 2 24.6Isolates recovered from sampling activities outside the scope of CIPARS routine (or “core”) surveillance in the specified year.  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Azithromycin 378 4 4 0.5  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.4.2 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.88.4 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.6.9 0.5 Table 7 - Footnote 2Isolates recovered from sampling activities outside the scope of CIPARS routine (or “core”) surveillance in the specified year.  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Cefoxitin 378 2 4 1.9  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.24.6 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.62.4 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.8.5 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2.6 Table 7 - Footnote 1 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1.3 Table 7 - Footnote 2 0.5Isolates recovered from sampling activities outside the scope of CIPARS routine (or “core”) surveillance in the specified year.  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Gentamicin 378 0.50 1 3.7  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2.4 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.75.9 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.17.5 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.3 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.3 Table 7 - Footnote 1 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.1.9 Table 7 - Footnote 2 1.9Isolates recovered from sampling activities outside the scope of CIPARS routine (or “core”) surveillance in the specified year.  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Kanamycin 378 <=8 <=8 5.3  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.93.9 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.5 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.3  Table 7 - Footnote 2 5.3Isolates recovered from sampling activities outside the scope of CIPARS routine (or “core”) surveillance in the specified year.  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Nalidixic acid 378 4 4 2.4  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.3 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.26.5 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.66.9 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3.7 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.3 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.0.5 Table 7 - Footnote 2 1.9Isolates recovered from sampling activities outside the scope of CIPARS routine (or “core”) surveillance in the specified year.  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Streptomycin 378 <=32 >64 27.5  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.72.5 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.5.3 Table 7 - Footnote 2 22.2Isolates recovered from sampling activities outside the scope of CIPARS routine (or “core”) surveillance in the specified year.  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Trimethoprim-sulfamethoxazole 378 <=0.12 0.25 7.1  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.86.5 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.6.3 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.0.3 Table 7 - Footnote 2 6.9Isolates recovered from sampling activities outside the scope of CIPARS routine (or “core”) surveillance in the specified year.  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
III Chloramphenicol 378 8 >32 21.4  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.3 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.17.5 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.57.9 Table 7 - Footnote 1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2.9  Table 7 - Footnote 2 21.4Isolates recovered from sampling activities outside the scope of CIPARS routine (or “core”) surveillance in the specified year.  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Sulfisoxazole 378 64 >256 31.2  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.4.8 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.31.2 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.31.5 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.3 31.2 Table 7 - Footnote 2Isolates recovered from sampling activities outside the scope of CIPARS routine (or “core”) surveillance in the specified year.
Tetracycline 378 <=4 >32 29.1  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.70.9 Table 7 - Footnote 1 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.0.5 Table 7 - Footnote 2 Percentage of isolates that were resistant to the antimicrobial according to the predefined resistance breakpoint.13.8 14.8Isolates recovered from sampling activities outside the scope of CIPARS routine (or “core”) surveillance in the specified year.  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
IV  

Table 8. Distribution of minimum inhibitory concentrations in Salmonella 4,[5],12:i:-
Antimicrobial n Percentiles % R Distribution (%) of MICs (µg/mL)
MIC 50 MIC 90 ≤ 0.015 0.03 0.06 0.12 0.25 0.5 1 2 4 8 16 32 64 128 256 >256
I Amoxicillin-clavulanic acid 122 <=1 8 2.5  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.65.6 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.6 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.12.3 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.16.4 Table 8 - Footnote 1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.6 0.8 Table 8 - Footnote 2 1.6Isolates recovered from sampling activities outside the scope of CIPARS routine (or “core”) surveillance in the specified year.  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Ceftiofur 122 1 1 1.6  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.23.0 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.73.8 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.6 Table 8 - Footnote 1  Table 8 - Footnote 2 1.6Isolates recovered from sampling activities outside the scope of CIPARS routine (or “core”) surveillance in the specified year.  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Ceftriaxone 122 <=0.25 <=0.25 1.6  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.98.4  Table 8 - Footnote 1  Table 8 - Footnote 2 0.8 0.8  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Ciprofloxacin 122 <=0.015 <=0.015 0.8 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.95.9 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3.3  Table 8 - Footnote 1  Table 8 - Footnote 2 0.8  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
II Ampicillin 122 <=1 >32 32.8  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.64.8 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2.5   Table 8 - Footnote 1  Table 8 - Footnote 2 32.8Isolates recovered from sampling activities outside the scope of CIPARS routine (or “core”) surveillance in the specified year.  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Azithromycin 122 4 4 2.5  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.4.9 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.91.0 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.6 2.5Table 8 - Footnote 2Isolates recovered from sampling activities outside the scope of CIPARS routine (or “core”) surveillance in the specified year.  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Cefoxitin 122 2 2 1.6  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.36.9 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.56.6 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.3.3 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.6 Table 8 - Footnote 1  Table 8 - Footnote 2 1.6Isolates recovered from sampling activities outside the scope of CIPARS routine (or “core”) surveillance in the specified year.  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Gentamicin 122 0.50 1 0.8  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.6 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.81.1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.16.4   Table 8 - Footnote 1  Table 8 - Footnote 2 0.8Isolates recovered from sampling activities outside the scope of CIPARS routine (or “core”) surveillance in the specified year.  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Kanamycin 122 <=8 <=8 2.5  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.96.7 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.8  Table 8 - Footnote 2 2.5Isolates recovered from sampling activities outside the scope of CIPARS routine (or “core”) surveillance in the specified year.  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Nalidixic acid 122 4 4 0.8  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.35.2 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.62.3 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.6 0.8Table 8 - Footnote 2  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Streptomycin 122 <=32 >64 31.1  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.68.9 0.8Table 8 - Footnote 2 30.3Isolates recovered from sampling activities outside the scope of CIPARS routine (or “core”) surveillance in the specified year.  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Trimethoprim-sulfamethoxazole 122 <=0.12 <=0.12 4.1  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.95.1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.8  Table 8 - Footnote 2 4.1Isolates recovered from sampling activities outside the scope of CIPARS routine (or “core”) surveillance in the specified year.  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
III Chloramphenicol 122 8 8 2.5  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.41.0 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.55.7 Table 8 - Footnote 1 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.8 0.8Table 8 - Footnote 2 1.6Isolates recovered from sampling activities outside the scope of CIPARS routine (or “core”) surveillance in the specified year.  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
Sulfisoxazole 122 64 >256 30.3  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.1.6 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.18.9 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.45.9 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.2.5 Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.0.8 30.3Table 8 - Footnote 2Isolates recovered from sampling activities outside the scope of CIPARS routine (or “core”) surveillance in the specified year.
Tetracycline 122 <=4 >32 41.8  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity Percentage of isolates that were susceptible to the antimicrobial according to the predefined susceptibility breakpoint.58.2 Table 8 - Footnote 1  Table 8 - Footnote 2 41.8Isolates recovered from sampling activities outside the scope of CIPARS routine (or “core”) surveillance in the specified year.  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity  Discontinuation or no surveillance activity
IV  
Report a problem or mistake on this page
Please select all that apply:

Thank you for your help!

You will not receive a reply. For enquiries, contact us.

Date modified: